Anticoagulation in pulmonary arterial hypertension - association with mortality, healthcare utilization, and quality of life: The Pulmonary Hypertension Association Registry (PHAR).
anticoagulation
pulmonary arterial hypertension
pulmonary hypertension
quality of life
Journal
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
ISSN: 1557-3117
Titre abrégé: J Heart Lung Transplant
Pays: United States
ID NLM: 9102703
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
received:
10
04
2022
revised:
29
07
2022
accepted:
22
08
2022
pubmed:
24
9
2022
medline:
30
11
2022
entrez:
23
9
2022
Statut:
ppublish
Résumé
Routine long-term anticoagulation in pulmonary arterial hypertension (PAH) is controversial. To date, anticoagulation has been found to be beneficial or neutral in idiopathic disease (IPAH) and neutral-to-harmful in connective tissue disease (CTD-PAH). We sought to examine the association between anticoagulation and mortality, healthcare utilization, and quality of life (QoL) in PAH. The PHAR is a prospective registry of PAH patients referred to 58 pulmonary hypertension care centers in the United States. We compared patients who received anticoagulation during enrollment (questionnaire documented) to those who did not. Cox proportional hazard models were used for mortality, Poisson multivariate regression models for healthcare utilization, and generalized estimating equations for QOL RESULTS: Of 1175 patients included, 316 patients were treated with anticoagulation. IPAH/hereditary PAH (HPAH) comprised 46% of the cohort and CTD-PAH comprised 33%. After adjustment for demographics, clinical characteristics, site and disease severity, anticoagulation was not associated with mortality in the overall population (HR, 1.00; 95% CI, 0.72-1.36), IPAH/HPAH (HR, 1.19; 95% CI, 0.74-1.94), or CTD-PAH (HR 0.87; 95% CI, 0.53-1.42). Anticoagulation was associated with an increased rate of emergency department visits (IRR: 1.41), hospitalizations (IRR: 1.30), and hospital days (IRR 1.33). QOL measured by emPHasis-10 score was worse in patients receiving anticoagulation (mean difference 1.74; 95% CI 0.40-3.09). Anticoagulation is not associated with higher mortality, but is associated with increased healthcare utilization in the PHAR. PAH-specific QoL may be worse in patients receiving anticoagulation. The risks and benefits surrounding routine prescription of anticoagulation for PAH should be carefully considered.
Sections du résumé
BACKGROUND
Routine long-term anticoagulation in pulmonary arterial hypertension (PAH) is controversial. To date, anticoagulation has been found to be beneficial or neutral in idiopathic disease (IPAH) and neutral-to-harmful in connective tissue disease (CTD-PAH). We sought to examine the association between anticoagulation and mortality, healthcare utilization, and quality of life (QoL) in PAH.
METHODS
The PHAR is a prospective registry of PAH patients referred to 58 pulmonary hypertension care centers in the United States. We compared patients who received anticoagulation during enrollment (questionnaire documented) to those who did not. Cox proportional hazard models were used for mortality, Poisson multivariate regression models for healthcare utilization, and generalized estimating equations for QOL RESULTS: Of 1175 patients included, 316 patients were treated with anticoagulation. IPAH/hereditary PAH (HPAH) comprised 46% of the cohort and CTD-PAH comprised 33%. After adjustment for demographics, clinical characteristics, site and disease severity, anticoagulation was not associated with mortality in the overall population (HR, 1.00; 95% CI, 0.72-1.36), IPAH/HPAH (HR, 1.19; 95% CI, 0.74-1.94), or CTD-PAH (HR 0.87; 95% CI, 0.53-1.42). Anticoagulation was associated with an increased rate of emergency department visits (IRR: 1.41), hospitalizations (IRR: 1.30), and hospital days (IRR 1.33). QOL measured by emPHasis-10 score was worse in patients receiving anticoagulation (mean difference 1.74; 95% CI 0.40-3.09).
CONCLUSIONS
Anticoagulation is not associated with higher mortality, but is associated with increased healthcare utilization in the PHAR. PAH-specific QoL may be worse in patients receiving anticoagulation. The risks and benefits surrounding routine prescription of anticoagulation for PAH should be carefully considered.
Identifiants
pubmed: 36150996
pii: S1053-2498(22)02085-X
doi: 10.1016/j.healun.2022.08.019
pmc: PMC10329839
mid: NIHMS1910117
pii:
doi:
Substances chimiques
hydralazine 4-anisaldehyde hydrazone
61641-43-8
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1808-1818Subventions
Organisme : NHLBI NIH HHS
ID : K24 HL155891
Pays : United States
Informations de copyright
Copyright © 2022 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Funding Sources None
Références
Med Care. 1996 Mar;34(3):220-33
pubmed: 8628042
Health Qual Life Outcomes. 2008 Aug 21;6:65
pubmed: 18718016
Chest. 2018 Oct;154(4):848-861
pubmed: 29705220
Chest. 2019 Mar;155(3):565-586
pubmed: 30660783
Circulation. 1984 Oct;70(4):580-7
pubmed: 6148159
Clin Rheumatol. 2020 Jan;39(1):19-26
pubmed: 31087225
Pulm Circ. 2017 Jul-Sep;7(3):692-701
pubmed: 28677986
Pulm Circ. 2018 Jul-Sep;8(3):2045894018790316
pubmed: 29969045
Jpn Circ J. 1993 Jan;57(1):63-9
pubmed: 8437343
Eur Heart J. 2016 Jan 1;37(1):67-119
pubmed: 26320113
Eur Respir J. 2021 Feb 25;57(2):
pubmed: 33243844
Thromb Res. 2020 Dec;196:251-256
pubmed: 32920295
Drug Discov Today. 2014 Aug;19(8):1230-5
pubmed: 24747560
Acta Med Scand. 1966 Feb;179(2):197-212
pubmed: 5908975
Circulation. 2014 Jan 7;129(1):57-65
pubmed: 24081973
Eur Respir J. 2013 Apr;41(4):872-8
pubmed: 22936704
Circulation. 1989 Nov;80(5):1198-206
pubmed: 2805258
Circulation. 2015 Dec 22;132(25):2403-11
pubmed: 26510696
Circ Cardiovasc Qual Outcomes. 2018 Sep;11(9):e004757
pubmed: 30354550
Pulm Circ. 2019 Dec 23;9(4):2045894019895451
pubmed: 31903185
Circulation. 2015 Dec 22;132(25):2360-2
pubmed: 26510695
Chest. 1997 Sep;112(3):714-21
pubmed: 9315805
Eur Respir J. 2021 Feb 25;57(2):
pubmed: 32631835
Thromb Res. 2014 May;133(5):790-4
pubmed: 24642007
Eur Respir J. 2014 Apr;43(4):1106-13
pubmed: 24232702
Health Qual Life Outcomes. 2013 Oct 03;11:161
pubmed: 24088389
N Engl J Med. 1992 Jul 9;327(2):76-81
pubmed: 1603139
Am J Cardiol. 2005 Jan 15;95(2):199-203
pubmed: 15642552
Arthritis Res Ther. 2017 Jun 2;19(1):122
pubmed: 28576149
Thromb Res. 2017 Dec;160:83-90
pubmed: 29127864